The small molecule BI-2852 induces a nonfunctional dimer of KRAS
- PMID: 32047043
- PMCID: PMC7035607
- DOI: 10.1073/pnas.1918164117
The small molecule BI-2852 induces a nonfunctional dimer of KRAS
Conflict of interest statement
Competing interest statement: F.M. is a consultant for the following companies: AduroBiotech; Amgen; Daiichi, Ltd.; PellePharm; Pfizer, Inc.; PMV Pharma; and Portola Pharmaceuticals. F.M. is Scientific Director of the National Cancer Institute RAS Initiative at Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. F.M. is a consultant for and cofounder of the following companies: Avidity, BridgeBio, KGen, and Quartz.
Figures

Comment in
-
Reply to Tran et al.: Dimeric KRAS protein-protein interaction stabilizers.Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3365-3367. doi: 10.1073/pnas.1921236117. Epub 2020 Feb 11. Proc Natl Acad Sci U S A. 2020. PMID: 32047042 Free PMC article. No abstract available.
Comment on
-
Drugging an undruggable pocket on KRAS.Proc Natl Acad Sci U S A. 2019 Aug 6;116(32):15823-15829. doi: 10.1073/pnas.1904529116. Epub 2019 Jul 22. Proc Natl Acad Sci U S A. 2019. PMID: 31332011 Free PMC article.
Similar articles
-
Researchers Reveal Another KRAS Inhibitor.Cancer Discov. 2019 Sep;9(9):1152. doi: 10.1158/2159-8290.CD-NB2019-092. Epub 2019 Aug 6. Cancer Discov. 2019. PMID: 31387866
-
Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.BMC Cancer. 2015 May 9;15:381. doi: 10.1186/s12885-015-1360-4. BMC Cancer. 2015. PMID: 25956913 Free PMC article.
-
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.Sci Rep. 2019 Jan 24;9(1):648. doi: 10.1038/s41598-018-37059-8. Sci Rep. 2019. PMID: 30679620 Free PMC article.
-
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.Cold Spring Harb Perspect Med. 2018 Aug 1;8(8):a031518. doi: 10.1101/cshperspect.a031518. Cold Spring Harb Perspect Med. 2018. PMID: 29101114 Free PMC article. Review.
-
Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?Semin Cancer Biol. 2019 Feb;54:114-120. doi: 10.1016/j.semcancer.2018.01.002. Epub 2018 Jan 5. Semin Cancer Biol. 2019. PMID: 29307569 Review.
Cited by
-
Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene-A Literature Review and Single-Center Experience.Biomedicines. 2024 Jan 31;12(2):325. doi: 10.3390/biomedicines12020325. Biomedicines. 2024. PMID: 38397927 Free PMC article. Review.
-
A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer.Protein Sci. 2021 Aug;30(8):1535-1553. doi: 10.1002/pro.4125. Epub 2021 May 31. Protein Sci. 2021. PMID: 34008902 Free PMC article. Review.
-
Crystal Packing Reveals a Potential Autoinhibited KRAS Dimer Interface and a Strategy for Small-Molecule Inhibition of RAS Signaling.Biochemistry. 2023 Nov 21;62(22):3206-3213. doi: 10.1021/acs.biochem.3c00378. Epub 2023 Nov 8. Biochemistry. 2023. PMID: 37938120 Free PMC article.
-
Loss of wild type KRAS in KRASMUT lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors.Lung Cancer. 2021 Mar;153:73-80. doi: 10.1016/j.lungcan.2020.12.032. Epub 2021 Jan 2. Lung Cancer. 2021. PMID: 33465697 Free PMC article.
-
GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf.ACS Cent Sci. 2020 Oct 28;6(10):1753-1761. doi: 10.1021/acscentsci.0c00514. Epub 2020 Sep 23. ACS Cent Sci. 2020. PMID: 33145412 Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous